ReviewOncology reviews2026
Sexual dysfunction after cancer: gender differences, tumor-specific patterns, and implications for sexual medicine practice.
Review in Oncology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sexual health is a central component of wellbeing, identity, and intimate relationships, yet it remains insufficiently addressed in cancer care. Cancer treatments disrupt sexual functioning through interacting physical, hormonal, psychological, and relational mechanisms, leading to persistent and often under-recognized sexual dysfunction among survivors. Aim: To synthesize current evidence on cancer-related sexual dysfunction, assessment strategies, and therapeutic interventions, with a focus on gender differences, tumor-site specificity, and implications for sexual medicine practice. Methods: This narrative review integrates evidence from population-based studies, clinical guidelines, and systematic reviews addressing sexual dysfunction across cancer types. Gender-specific patterns and biopsychosocial mechanisms were examined to inform assessment and management within sexual medicine and survivorship care. Results: Women commonly experience multidimensional and frequently "invisible" sexual difficulties, including reduced desire and arousal, orgasmic dysfunction, dyspareunia, vaginal atrophy, body image disturbance, and fertility-related distress. Men more often present with overt functional impairments, particularly erectile and ejaculatory dysfunction following prostate and other male cancer treatments. Existing assessment tools capture selected aspects of sexual function but often fail to reflect the full biopsychosocial complexity of post-cancer sexuality. Effective management requires integrated interventions combining medical and pharmacological therapies, physical rehabilitation, psychosexual and couples counseling, and structured communication models. Tailored, gender- and tumor-specific approaches embedded within multidisciplinary survivorship pathways are essential, including culturally competent care for sexual and gender minority patients. Conclusion: Sexual dysfunction is a prevalent and clinically relevant consequence of cancer. Comprehensive assessment and personalized, multidisciplinary interventions are essential components of high-quality sexual medicine care for cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.